Eisai Co., Ltd. (TSE: 4523) announced today that Vasolan(R) Tablets 40mg (generic name: verapamil hydrochloride) received approval for the additional indications of the treatment of atrial fibrillation/flutter and paroxysmal supraventricular tachycardia. This approval makes Vasolan the first oral form of calcium channel blockers approved for the treatment of tachyarrhythmia in Japan.
Vasolan is a calcium channel blocker with coronary/peripheral vasodilator actions. It has been used to treat ischaemic heart disease for more than forty years. For many years, Vasolan has been used to treat arrhythmia in the U.S. and European countries because of its beneficially effects on heart rate control in artial fibrillation/flutter and stopping/preventing paroxysmal supraventricular tachycardia. In Japan, Vasolan for intravenous injection 5mg that contains the same active ingredients as the oral form tablet has been approved for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia). The additional indications approved today for the oral form of Vasolan will provide a wider range of treatment options for patients who are suffering from tachyarrhythmia.
No comments:
Post a Comment